Rosa Hoekstra is reader in global perspectives on neurodevelopmental disorders at Kings College London in the United Kingdom.
Rosa Hoekstra
Lecturer
Kings College London
From this contributor
Remembering Zemi Yenus: An ambassador for autism in Africa
Zemi Yenus was the mother of a child with autism, founder of Ethiopia’s first school for autistic children and a tireless advocate for autism awareness and research in Africa.
Remembering Zemi Yenus: An ambassador for autism in Africa
How to address autism in Ethiopia and other low-income nations
Even short programs with a focus on mental health can train community health workers to help children with autism in Ethiopia and elsewhere.
How to address autism in Ethiopia and other low-income nations
Explore more from The Transmitter
Exclusive: Brain and spinal cord institute halts research, citing funding problems
The Burke Neurological Institute, which calls itself “the only research institute in the U.S. dedicated to finding treatments to repair the brain and spinal cord,” ceased research operations on 22 May.
Exclusive: Brain and spinal cord institute halts research, citing funding problems
The Burke Neurological Institute, which calls itself “the only research institute in the U.S. dedicated to finding treatments to repair the brain and spinal cord,” ceased research operations on 22 May.
When autistic kids grow up, Chapter 1: Those people
What leads an autism researcher to publish an intentionally inflammatory paper accusing the NIH of discrimination?
When autistic kids grow up, Chapter 1: Those people
What leads an autism researcher to publish an intentionally inflammatory paper accusing the NIH of discrimination?
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.